Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Could disease-modifying HIV vaccines cause population-level perversity?

Smith RJ, Blower SM.

Lancet Infect Dis. 2004 Oct;4(10):636-9.

PMID:
15451492
2.

Is population-level perversity a likely outcome of mass vaccination against HIV?

Bogaards JA, van Ballegooijen WM, Jan Weverling G, Boerlijst MC, Goudsmit J.

Lancet Infect Dis. 2005 May;5(5):254; author reply 255-6. No abstract available.

PMID:
15854875
3.

Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus.

Davenport MP, Ribeiro RM, Chao DL, Perelson AS.

J Virol. 2004 Oct;78(20):11340-51.

4.

Predicting the potential public health impact of disease-modifying HIV vaccines in South Africa: the problem of subtypes.

Blower SM, Bodine EN, Grovit-Ferbas K.

Curr Drug Targets Infect Disord. 2005 Jun;5(2):179-92. Review.

PMID:
15975023
5.

Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda.

Gray RH, Li X, Wawer MJ, Gange SJ, Serwadda D, Sewankambo NK, Moore R, Wabwire-Mangen F, Lutalo T, Quinn TC; Rakai Project Group.

AIDS. 2003 Sep 5;17(13):1941-51.

PMID:
12960827
6.

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamczer D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B.

Lancet Infect Dis. 2014 Apr;14(4):291-300. doi: 10.1016/S1473-3099(13)70343-8. Epub 2014 Feb 11.

7.

Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.

Sánchez-Ramón S, Bellón JM, Resino S, Cantó-Nogués C, Gurbindo D, Ramos JT, Muñoz-Fernández MA.

Pediatrics. 2003 Feb;111(2):E168-75.

PMID:
12563091
8.

A review and update on HIV infection and the AIDS epidemic in the adolescent and adult.

Kahn MA.

J Tenn Dent Assoc. 2000 Fall;80(4):21-7. No abstract available.

PMID:
11323867
9.

T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients.

Abulafia-Lapid R, Bentwich Z, Keren-Zur Y, Cohen IR, Atlan H.

J Clin Virol. 2004 Dec;31 Suppl 1:S48-54.

PMID:
15567094
10.

Effect of influenza vaccination on disease progression among HIV-infected persons.

Sullivan PS, Hanson DL, Dworkin MS, Jones JL, Ward JW; Adult and Adolescent Spectrum of HIV Disease Investigators.

AIDS. 2000 Dec 1;14(17):2781-5.

PMID:
11125897
11.
12.

Analytic insights into the population level impact of imperfect prophylactic HIV vaccines.

Abu-Raddad LJ, Boily MC, Self S, Longini IM Jr.

J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):454-67.

PMID:
17554215
13.

High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load.

Santos-Oliveira JR, Giacoia-Gripp CB, Alexandrino de Oliveira P, Amato VS, Lindoso JÂ, Goto H, Oliveira-Neto MP, Mattos MS, Grinsztejn B, Morgado MG, Da-Cruz AM.

BMC Infect Dis. 2010 Dec 20;10:358. doi: 10.1186/1471-2334-10-358.

14.
15.

Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV.

Fonseca MG, Forsythe S, Menezes A, Vuthoori S, Possas C, Veloso VG, Lucena Fde F, Stover J.

PLoS One. 2010 Jul 23;5(7):e11736. doi: 10.1371/journal.pone.0011736. Erratum in: PLoS One. 2010 Aug 18;5(8) doi: 10.1371/annotation/4fd10061-5a1e-4164-833e-34943a74301c.. Veloso, Valdiléa [corrected to Veloso, Valdiléa Gonçalves].

16.

Human immunodeficiency virus type-1 (HIV-1) disease progression and viral activity: a seroepidemiological and molecular study.

Bukhari SZ, Qazi JI, Ashshi AM, Zia N.

J Coll Physicians Surg Pak. 2012 Sep;22(9):565-9. doi: 09.2012/JCPSP.565569.

PMID:
22980609
17.

Evidence for extended age dependent maternal immunity in infected children: mother to child transmission of HIV infection and potential interventions including sulfatides of the human fetal adnexa and complementary or alternative medicines.

Bhargav H, Huilgol V, Metri K, Sundell IB, Tripathi S, Ramagouda N, Jadhav M, Raghuram N, Ramarao NH, Koka PS.

J Stem Cells. 2012;7(3):127-53. doi: jsc.2012.7.3.127.

PMID:
23619381
18.

[Reactogenicity, safety, immunogenicity and prophylactic effectiveness of polysaccharide pneumococcus vaccine during immunization of HIV-infected patients].

Fel'dblium IV, Nikolenko VV, Vorob'eva NN, Ivanova ÉS, Shmagel' NG, Khafizov KM, Iurganova GA, Zverev SIa.

Zh Mikrobiol Epidemiol Immunobiol. 2013 May-Jun;(3):52-60. Russian.

PMID:
24000594
19.
20.

The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: a modeling study.

Nagelkerke NJ, Hontelez JA, de Vlas SJ.

Vaccine. 2011 Aug 18;29(36):6079-85. doi: 10.1016/j.vaccine.2011.06.048. Epub 2011 Jun 28.

PMID:
21718745

Supplemental Content

Support Center